An engineered growth factor sold as a research chemical. No human trials exist. It's banned in all sport at all times, and the FDA-approved version of the same molecule carries a cancer contraindication.
IGF-1 LR3 is a laboratory-engineered version of insulin-like growth factor 1, a hormone your body produces that drives tissue growth. The engineering had one goal: make it last longer and hit harder than the natural version. It works. It's roughly three times more potent, and it stays active in circulation for around a day instead of minutes. It's sold online for muscle growth and recovery. Here's what to know before reading any further. There has never been a human clinical trial of IGF-1 LR3. It's prohibited in sport at all times by the World Anti-Doping Agency, which names it by category on the Prohibited List. And the closest FDA-approved relative, a prescription drug called Increlex, is contraindicated in anyone with active or suspected cancer, with the label instructing parents to watch treated children for new growths. That drug is the gentler molecule.
Native IGF-1 is a chain of 70 amino acids. IGF-1 LR3 has 83. The extra 13 sit at one end of the molecule, and a single amino acid at position 3 has been swapped, arginine in place of glutamic acid, which is where the "R3" in the name comes from. Both changes serve the same purpose. Your body regulates IGF-1 by binding most of it to carrier proteins, called IGF binding proteins, which hold it inactive until it's needed. The modifications in LR3 make it bind those carriers poorly. It slips past the system that was supposed to control it. That's the entire design. It's sold as a research reagent for cell culture and bioprocessing work, not as a drug. It has never been a drug candidate.
The biological context for IGF-1 LR3 centers on skeletal muscle, the IGF-1 receptor, and glucose metabolism — the systems a growth factor engineered to signal harder and longer would touch first. Read this as a systems-level orientation, not as evidence that the compound is safe or effective in people; there are no human studies to draw on. Mechanism, animal data, and the regulatory record on the approved IGF-1 drug belong in separate lanes, and this page keeps them apart.
IGF-1 LR3 binds to the IGF-1 receptor on cells and switches on the growth machinery behind it, principally the PI3K/Akt and MAPK pathways. In muscle, that means protein synthesis, glucose uptake, and satellite cell activation. This is well-understood biology and nobody disputes it. Because the compound evades the binding proteins, it produces a stronger, flatter, far longer signal than natural IGF-1 ever does. There's a second detail worth understanding. The IGF-1 receptor is closely related to the insulin receptor, and IGF-1 has insulin-like effects on blood sugar. That's not a quirk. It's built into what the molecule is, and it's why the approved IGF-1 drug caused low blood sugar in a large fraction of the children who took it under medical supervision.
Human data. The reviewed sources do not include direct human studies of IGF-1 LR3 — there has never been a human clinical trial of it, for safety or for effectiveness, in any population. Any claim about what it does in people is inference from animal work, and this page treats those claims as unproven rather than established.
Preclinical data. There are no human trials of IGF-1 LR3. Not for safety, not for effectiveness, not at any exposure, in any population. What exists is animal work. In the foundational rat study, the LR3 analog was one and a half to two times more potent than natural IGF-1 when infused continuously. But when given by once-daily injection instead, that advantage shrank considerably, and for reversing muscle loss it was barely better than natural IGF-1 at all. That nuance rarely survives into the marketing. Everything you'll read about muscle growth in humans is extrapolation from rodents, plus anecdote from people who bought it online. The honest position is that the mechanism is sound, the animal data are real but more mixed than advertised, and the human evidence base is empty.
Anecdotal discussion. Online, IGF-1 LR3 is sold for muscle growth on the strength of its mechanism and rodent data, with the empty human record and the safety and anti-doping context left out. Anecdote and vendor claims can explain why the compound is visible, but they cannot establish effectiveness, product identity, or safety — and what is sold as a research chemical is not a verified pharmaceutical and has been through none of the controls that word implies.
This deserves its own space because it's the most serious thing here and it's frequently waved away. The IGF-1 receptor is an established growth pathway in several cancers. That's textbook. The question is whether raising IGF-1 raises risk. Large prospective studies say the association is real. A UK Biobank analysis following nearly 400,000 cancer-free people found higher circulating IGF-1 associated with higher incidence of breast, prostate, and colorectal cancer. A pooled analysis combining individual data from seventeen prospective studies found men in the highest fifth of IGF-1 had about 29% higher odds of prostate cancer than those in the lowest, and IGF-1 was the only factor that survived adjustment for the others. Genetic evidence has since suggested these relationships may be causal, not merely correlated. Now the boundary, stated plainly. All of that concerns ordinary IGF-1 levels varying within the normal human range. Nobody has studied people taking a supraphysiological analog designed to bypass the body's controls, because that study would be unethical to run. So we cannot tell you that IGF-1 LR3 causes cancer. What we can tell you is that the pathway this compound exists to hyperactivate is the same pathway that, at ordinary levels, tracks with cancer risk across hundreds of thousands of people, and that the FDA contraindicates the approved IGF-1 drug in anyone with active or suspected malignancy while instructing parents of treated children to report any new growth immediately. That is the shape of the evidence. Draw your own conclusion.
The World Anti-Doping Agency's Prohibited List names insulin-like growth factor 1 and its analogues under growth factors. IGF-1 LR3 is, by definition, an analogue. It is prohibited at all times, in and out of competition. Beyond that, IGF-1 concentration is one of the markers tracked in the Athlete Biological Passport, so anti-doping authorities can flag abnormal patterns in an athlete's blood profile over time. Using it is an anti-doping rule violation.
This section matters more than any other on this page, so read it carefully. There's no human safety data for IGF-1 LR3 itself. But we can look at what happened with mecasermin, the FDA-approved recombinant IGF-1 sold as Increlex, prescribed to children with a severe IGF-1 deficiency, in a clinical setting with glucose monitoring and supervision. In the trials, 42% of patients experienced low blood sugar at least once. Several had episodes severe enough to require assistance, and some had seizures or lost consciousness. The label also documents intracranial hypertension, enlargement of lymphoid tissue requiring periodic examination, kidney and spleen enlargement, and anaphylaxis serious enough to require hospitalization. That's the supervised, gentler molecule, in patients who genuinely needed it. IGF-1 LR3 is more potent, evades the body's regulatory system, and is sold to people with no deficiency, no monitoring, and no prescriber. Nothing on this page is medical advice.
IGF-1 LR3 reaches muscle-growth and recovery conversations because a growth factor engineered to signal harder and longer is an obvious lever to reach for. The honest reading is narrower: the human evidence base is empty, the approved IGF-1 drug carries a malignancy contraindication, and for anyone in tested sport it is prohibited at all times. The useful role for this page is orientation and caution, not encouragement.
Because the point of this page is restraint, it does not translate the mechanism into a reason to use the compound. What the biology suggests is potency; what the human evidence offers on safety and effectiveness is nothing at all, and potency without a safety record is a reason for caution rather than interest.
Across the Aeternus library, the practical standard is claim matching. A mechanism belongs in mechanism language, a cell or animal model belongs in preclinical language, and a human trial belongs in population-specific human-evidence language. This keeps the entry useful for readers who want orientation without turning biology into personal direction. The strongest interpretation is usually the narrowest accurate one: name the pathway, name the evidence type, name the limits, and leave space for uncertainty where the sources do not answer the question. That standard also protects the reader from a common mistake in this category: assuming that biological relevance automatically creates a usable strategy. It does not. Evidence becomes useful when the claim, source type, population, endpoint, and safety context all line up.
It isn't approved for anything, anywhere. It isn't the same thing as Increlex, the prescription IGF-1 drug, which is sequence-identical to the natural hormone, has a short half-life, and is given for a diagnosed deficiency under supervision. LR3 was deliberately built to be more aggressive than that. It isn't backed by human evidence, because none has been generated. It isn't cleared for athletes under any circumstance. And it isn't sold to you as a pharmaceutical product, which means nothing about its purity or its actual contents has been verified. This page doesn't tell you how to obtain it or use it, and nothing here encourages either.
We've written about compounds where the science was thin and the marketing was loud. This one is different, and more serious. The biology is not in question. IGF-1 LR3 almost certainly does what it says it does, and that's the problem, not the reassurance. The body maintains an elaborate system of carrier proteins to keep IGF-1 signaling within bounds, and this molecule was engineered specifically to defeat that system. The regulatory record on the mildest version of this drug reads like a warning: cancer contraindication, seizures from low blood sugar, enlarged organs, mandatory surveillance. Meanwhile the epidemiology suggests that even ordinary variation in IGF-1, within the range your own body produces, tracks with cancer risk. Of everything in this library, IGF-1 LR3 is the compound where we'd most want a reader to sit with the safety section, and where the gap between what's known and what's being sold is widest. Potent is not the same as safe. Sometimes it's the opposite.
